RE:Increasing revenues through pandemic!GoldenInvestor wrote: Looking at the Knight investor fact sheet, august 2022,
as the team have grown Knight, incorporating GBT, revenues have increased over $10MM TO $75.8MM.
YTD rev increase almost up by $28MM
EBITDA also cruising by 2021 by more than 2*!
$31mm vs $15mm
GI
Which is why it's really easy to grow overall revenue based on adding a single drug to ROW.
Imagine what you could do with a couple drugs - OR - by adding a portfolio.
Same thing if you can bring a branded generic (or a few branded generics) online.
Lots of ways to grow - early days.
Also can move into additional geographies ... but ... that's likely something for down the road.